Clinical Cardiology

View the latest content related to this topic

News Conference News AHA 2024

Lipid Fluctuations Over Time May Portend Dementia: ASPREE

Total and LDL cholesterol variability over time may be a biomarker for higher dementia risk and cognitive decline.

Yael L. Maxwell

November 15, 2024

Slides

See all

Presentation TCT 2024

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presenter: Ryo Hikida

October 29, 2024

Presentation TCT 2024

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Presenter: David Kwon

October 29, 2024

Presentation TCT 2024

Debate Con: RDN Will Ultimately Be a Niche Therapy

Presenter: Andrew Sharp

October 29, 2024

Presentation TCT 2024

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Presenter: Raymond R. Townsend

October 29, 2024

Presentation TCT 2024

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Presenter: Michael A. Weber

October 29, 2024

News

See all

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

By Michael O'Riordan

November 16, 2024

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

By Michael O'Riordan

November 16, 2024

News Conference News AHA 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

By Yael L. Maxwell

November 16, 2024

News Conference News AHA 2024

Lipid Fluctuations Over Time May Portend Dementia: ASPREE

By Yael L. Maxwell

November 15, 2024

News Conference News AHA 2024

US Obesity Epidemic Continues to Skyrocket, With No End in Sight

By Michael O'Riordan

November 15, 2024

New York Valves 2024

June 5

June 07, 2024

EuroPCR 2024

May 14

May 17, 2024

ACC 2024

April 6

April 08, 2024

Videos on This Topic

See all

Advertisement

Clinical Cardiology

Lipid Fluctuations Over Time May Portend Dementia: ASPREE

Slides

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Debate Con: RDN Will Ultimately Be a Niche Therapy

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

News

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Lipid Fluctuations Over Time May Portend Dementia: ASPREE

US Obesity Epidemic Continues to Skyrocket, With No End in Sight

More on This Topic

Conference Coverage

New York Valves 2024

EuroPCR 2024

ACC 2024

Videos on This Topic

Advertisement

Clinical Cardiology

Slides

News

More on This Topic

Conference Coverage

Videos on This Topic

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content